Cellectis Plans Phase 1 Trial of.HEAL-101 in China
Cellectis expects initial data in the second half of 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Cellectis Shares Preclinical Data, Plans China Trial for 2027
Cellectis presented expanded preclinical data for HEAL-101, an APOC3 base editor, and plans to start a Phase 1 investigator-initiated trial in China, with preliminary data expected in H2 2027.